RecruitingPhase 4ACTRN12617000983303

The causes of bradycardia in athletes

The effects of ivabradine under autonomic blockade in endurance athletes.


Sponsor

Baker Heart and Diabetes Institute

Enrollment

30 participants

Start Date

Jul 18, 2017

Study Type

Interventional

Conditions

Summary

It is well known that athletes have lower heart rates (bradycardia) than non-athletes. This is generally considered a healthy adaptation. However, bradycardia has been associated with the subsequent development of atrial fibrillation (AF), an arrhythmia known to increase the risk of heart failure, stroke and even death. Consequently, bradycardia could conceivably be associated with significant problems later in life. The reasons athletes have slow heart rates are not well understood. Traditionally changes in neural input (vagal tone) were thought to lead to bradycardia in athletes. However, several studies have demonstrated that even after blocking these inputs(autonomic blockade), athletes continue to have lower heart rates than non-athletes. The reasons for this are not known however recent research using athlete mice models suggests this is due to intrinsic changes within the heart by downregulation of the HCN4 gene. In the mouse model, the medication which blocks this gene, ivabradine, helped to equalize the heart rates in athlete and non-athlete mice. Our aim in this study is to understand the reason for lower heart rates in endurance athletes. Participants will undergo repeat testing under experimental conditions to help determine the causes of low heart rates in athletes. We hypothesize that ivabradine will be less effective in athletes, ie it will lower the heart rate of athletes less than nonathletes. This would suggest that bradycardia in athletes is associated with changes within the heart rather than reversible changes in neural inputs. This may provide some insights into the mechanism of atrial fibrillation in athletes.


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 50 Yearss

Inclusion Criteria3

  • Group 1 (Endurance athletes): Competing in endurance sport
  • Group 2 (Healthy Volunteers): Less than three hours of exercise per week
  • Group 3 (Endurance athletes with bradycardia): Endurance athletes with a resting heart rate less than 40

Exclusion Criteria13

  • Allergy to one of the medications
  • Asthma
  • Glaucoma
  • Urinary Retention/Prostate enlargement
  • Past history of psychosis
  • Ulcerative Colitis
  • Gastrointestinal Obstruction
  • Myasthenia gravis
  • Hypotension(low blood pressure
  • Smoker
  • Preexisting cardiac or lung disease
  • Pregnant or breast feeding
  • Contraindication to MRI

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Intervention: Autonomic blockade with single doses of intravenous metoprolol(0.2mg/kg) + intravenous atropine (0.04mg/kg) plus oral ivabradine 15mg Exposure: endurance sport participation A wash

Intervention: Autonomic blockade with single doses of intravenous metoprolol(0.2mg/kg) + intravenous atropine (0.04mg/kg) plus oral ivabradine 15mg Exposure: endurance sport participation A wash out period of at least 24 hours will occur before crossover to the control arm


Locations(1)

Baker Heart and Diabetes Institute - Melbourne

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12617000983303